NASDAQ$UFPT

UFP Technologies Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

UFP Technologies reported strong results driven by revenue growth and strategic initiatives.

UFP Technologies reported a strong first quarter with a 47% increase in revenue compared to Q1 2021, driven by 15% organic growth in the MedTech group. Net income increased to $4.9 million, or $0.64 per diluted share. The company also completed its third acquisition in six months and made progress on new manufacturing capabilities.

  • Revenue grew 47% versus Q1 2021, including 15% organic growth in the MedTech group.
  • Operating income increased despite absorbing $775,000 in one-time acquisition costs and navigating supply chain issues.
  • The company completed its third acquisition in six months, adding critical MedTech manufacturing capabilities in Ireland.
  • Production Qualification was completed in the new Tijuana, Mexico, facility in record time.

Headline financials

Total Revenue

$71.2M

Previous: $48.6M+46.6%
EPS (adj)

$0.64

Previous: $0.55+16.4%
Capital Expenditures

-$2.33M

Previous: -$1.45M-61.1%
Free Cash Flow

$2.52M

Previous: $2.71M-7.0%
Net Income

$4.86M

Previous: $4.16M+16.7%
Operating Income

$6.36M

Previous: $5.3M+20.0%
Gross Profit

$17.1M

Previous: $12.6M+35.9%
Cash & Equivalents

$3.65M

Previous: $25.4M-85.6%
Total Assets

$363M

Previous: $209M+73.7%
Stock-Based Comp

$692K

Previous: $501K+38.1%

Revenue & EPS history

UFP Technologies · Revenue · Quarterly

$71.2M

Q1 2022+46.6%vs Q1 2021
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

UFP Technologies · $6.8M total across 1 segment · Q3 2023

  • Medical
    $6.8M

Forward guidance

The company expects supply chain issues in the medical business to improve significantly late in Q2, and combined with a growing pipeline of product development opportunities, extensive backlog of open orders awaiting raw materials, and strong balance sheet, they are very bullish about their future.

Tailwinds

  • Supply chain issues in the medical business are expected to improve significantly late in Q2.
  • Growing pipeline of product development opportunities.
  • Extensive backlog of open orders awaiting raw materials.
  • Strong balance sheet.
  • New low-cost manufacturing capabilities in the Dominican Republic, Costa Rica, and Mexico.

Headwinds

  • Severity and duration of the COVID-19 pandemic and its impact on the markets.
  • Risks relating to decreased demand for products.
  • Risks relating to the potential closure of facilities or the unavailability of key personnel.
  • Risks that inventory or cash reserves may be insufficient.
  • Risks relating to the identification of suitable acquisition candidates and the successful execution of acquisition transactions.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+2.7%

Avg return

Earnings day

+3.1%

Avg return

5 days after

+5.5%

Avg return

30 days after

66%

43 / 65 earnings

Positive

+24.0%

Q1 2024

Best reaction

-11.6%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.2%-1.0%+1.1%
Q4 2025+0.3%-15.1%-21.2%
Q3 2025+12.2%+13.6%+8.6%
Q1 2025+11.2%+19.8%+23.6%
Q4 2024+9.4%-5.5%-15.7%
Q3 2024+23.8%+24.2%+4.5%
Q2 2024+2.8%-5.4%+7.7%
Q1 2024+24.0%+24.5%+26.4%
Q4 2023+10.5%+11.3%+26.2%
Q3 2023-11.6%-8.0%+6.9%
Q2 2023-5.5%-6.3%-9.7%
Q1 2023+5.8%+2.0%+13.9%
Q4 2022+10.8%+2.9%+16.5%
Q3 2022+16.4%+21.5%+31.6%
Q2 2022+11.2%+11.1%+14.1%
Q1 2022+5.9%+3.1%+14.2%
Q4 2021-1.0%-11.1%+1.3%
Q3 2021+4.1%+6.8%+7.6%
Q2 2021+9.6%+12.5%+14.8%
Q1 2021+8.1%+8.8%+15.4%
Q4 2020+1.4%-7.8%-0.7%
Q3 2020+13.2%+18.9%+25.0%
Q2 2020+3.7%+2.5%-6.4%
Q1 2020+1.3%+7.1%+10.0%
Q4 2019+3.0%-4.2%-28.6%
Q3 2019-0.2%+1.3%+7.7%
Q2 2019+2.6%-1.4%-2.2%
Q1 2019+2.8%+3.6%+5.0%
Q4 2018-1.4%-0.2%+8.6%
Q3 2018-0.8%-1.8%+5.1%
Q2 2018+2.7%+10.2%+7.6%
Q1 2018-0.6%-3.2%-6.2%
Q4 2017-3.3%-1.4%+3.7%
Q3 2017-10.1%-11.1%-9.0%
Q2 2017-3.3%-3.8%-8.0%
Q1 2017+1.7%+1.1%+4.9%
Q4 2016+0.4%+1.2%+5.7%
Q3 2016-4.6%-3.5%-4.6%
Q2 2016+3.3%+2.9%+7.5%
Q1 2016+1.3%
Q4 2015+5.6%
Q3 2015-0.6%
Q2 2015+12.7%
Q1 2015-2.7%
Q4 2014-7.5%
Q3 2014+0.9%
Q2 2014-2.1%
Q1 2014-1.2%
Q4 2013+0.1%
Q3 2013-0.9%
Q2 2013+1.4%
Q1 2013-3.4%
Q4 2012-0.6%
Q3 2012-2.5%
Q2 2012+1.3%
Q1 2011+2.5%
Q1 2012+0.6%
Q4 2009-3.0%
Q4 2011-3.0%
Q3 2010+2.6%
Q3 2011+2.6%
Q4 2010+1.3%
Q2 2010+1.3%
Q2 2011+1.3%
Q1 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro